$1.13
3.02% today
NYSE, Apr 03, 06:51 pm CET
ISIN
US35168W1036
Symbol
GUTS
Sector
Industry

Fractyl Health Stock price

$1.16
-0.40 25.64% 1M
-1.16 50.00% 6M
-0.90 43.69% YTD
-5.58 82.79% 1Y
-13.84 92.27% 3Y
-13.84 92.27% 5Y
-13.84 92.27% 10Y
NYSE, Closing price Wed, Apr 02 2025
+0.05 4.50%
ISIN
US35168W1036
Symbol
GUTS
Sector
Industry

Key metrics

Market capitalization $56.75m
Enterprise Value $51.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 575.44
P/S ratio (TTM) P/S ratio 630.56
P/B ratio (TTM) P/B ratio 1.99
Revenue (TTM) Revenue $90.00k
EBIT (operating result TTM) EBIT $-93.53m
Free Cash Flow (TTM) Free Cash Flow $-67.29m
Cash position $67.46m
EPS (TTM) EPS $-1.46
P/E forward negative
Short interest 11.92%
Show more

Is Fractyl Health a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Fractyl Health Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Fractyl Health forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Fractyl Health forecast:

Buy
100%

Financial data from Fractyl Health

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.09 0.09
-
100%
- Direct Costs 0.73 0.73
-
811%
-0.63 -0.63
-
-700%
- Selling and Administrative Expenses 22 22
-
24,167%
- Research and Development Expense 70 70
-
78,300%
-93 -93
-
-103,167%
- Depreciation and Amortization 0.68 0.68
-
756%
EBIT (Operating Income) EBIT -94 -94
-
-103,923%
Net Profit -69 -69
-
-76,322%

In millions USD.

Don't miss a Thing! We will send you all news about Fractyl Health directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fractyl Health Stock News

Neutral
GlobeNewsWire
2 days ago
New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of o...
Neutral
Seeking Alpha
about one month ago
Fractyl Health, Inc. (NASDAQ:GUTS ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Brian Luque – Head of Investor Relations and Corporate Development Harith Rajagopalan – Chief Executive Officer Lisa Davidson – Chief Financial Officer Conference Call Participants Mike Ulz – Morgan Stanley Michael DiFiore – Evercore ISI William Wood – B. Riley Securities Operator ...
Neutral
GlobeNewsWire
about one month ago
Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full study enrollment expected in summer 2025
More Fractyl Health News

Company Profile

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Head office United States
CEO Harith Rajagopalan
Employees 107
Founded 2010
Website www.fractyl.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today